Champions Oncology (CSBR) Capital Expenditures (2010 - 2026)

Champions Oncology (CSBR) has 17 years of Capital Expenditures data on file, last reported at $125000.0 in Q3 2026.

• On a quarterly basis, Capital Expenditures fell 56.29% year-over-year to $125000.0 in Q3 2026; TTM through Jul 2026 was $403000.0, a 40.3% decrease from a year earlier, with the FY2026 full-year figure at $564000.0, up 44.99% from the prior year.
• Capital Expenditures for Q3 2026 stood at $125000.0, down from $239000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $760000.0 in Q2 2023 and bottomed at -$39000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $316500.0 across 5 years, with a median of $262500.0 in 2025.
• The widest annual swing landed in 2025, when Capital Expenditures plunged 1200.0%; it then surged 712.82% in 2026.
• Year by year, Capital Expenditures stood at $604000.0 in 2022, then plunged by 86.92% to $79000.0 in 2023, then climbed by 18.99% to $94000.0 in 2024, then slumped by 97.87% to $2000.0 in 2025, then jumped by 6150.0% to $125000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $125000.0 in Q3 2026, $239000.0 in Q2 2026, and $37000.0 in Q1 2026.